Research analysts at Maxim Group assumed coverage on shares of Achieve Life Sciences (NASDAQ:ACHV) in a report issued on Friday, The Fly reports. The firm set a “buy” rating on the biopharmaceutical company’s stock.
Separately, LADENBURG THALM/SH SH set a $20.00 target price on Achieve Life Sciences and gave the stock a “buy” rating in a research note on Tuesday.
ACHV stock opened at $2.67 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.63 and a quick ratio of 2.63. Achieve Life Sciences has a one year low of $1.04 and a one year high of $6.58. The firm has a market cap of $18.19 million, a price-to-earnings ratio of -0.74 and a beta of 2.67.
Achieve Life Sciences (NASDAQ:ACHV) last posted its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter. As a group, sell-side analysts anticipate that Achieve Life Sciences will post -1.7 earnings per share for the current fiscal year.
In related news, major shareholder Armistice Capital Master Fund bought 12,813 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was acquired at an average price of $3.80 per share, for a total transaction of $48,689.40. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Richard Alistair Stewart bought 17,500 shares of the business’s stock in a transaction on Thursday, May 23rd. The stock was bought at an average price of $3.61 per share, with a total value of $63,175.00. The disclosure for this purchase can be found here. Corporate insiders own 6.80% of the company’s stock.
Several large investors have recently added to or reduced their stakes in ACHV. Searle & CO. purchased a new stake in shares of Achieve Life Sciences in the 1st quarter valued at about $237,000. Worth Venture Partners LLC raised its holdings in shares of Achieve Life Sciences by 180.1% in the 4th quarter. Worth Venture Partners LLC now owns 89,632 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 57,632 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Achieve Life Sciences by 13.4% in the 1st quarter. Renaissance Technologies LLC now owns 285,661 shares of the biopharmaceutical company’s stock valued at $923,000 after acquiring an additional 33,800 shares in the last quarter. Finally, Vanguard Group Inc raised its holdings in shares of Achieve Life Sciences by 169.3% in the 3rd quarter. Vanguard Group Inc now owns 35,468 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 22,299 shares in the last quarter. 16.20% of the stock is currently owned by hedge funds and other institutional investors.
Achieve Life Sciences Company Profile
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.
Featured Story: Trading Strategy Examples and Plans
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.